Abstract library

5 results for "Atlan".
#538 Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales
Introduction: SU is an oral multitargeted tyrosine kinase inhibitor approved in Europe for advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Adam Johns
Authors: Johns A, Eatock M, Johal S
#1804 Open-Label Multicentre Single-Arm Phase 2 Trial of Lanreotide Autogel (LAN) in Combination with Temozolomide (TMZ) in Patients with Advanced Well/Moderately Differentiated Neuroendocrine Tumours (NETs) of Lung and Thymus: ATLANT
Introduction: In phase 3 CLARINET study, LAN 120mg every 28 days significantly prolonged progression-free survival (PFS) vs placebo in pts with well-differentiated metastatic enteropancreatic NETs, but limited data exist for somatostatin analogues in advanced lung/thymic NETs. Evidence that TMZ may be active in thoracic NETs is mainly retrospective.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Piero Ferolla
#1041 Surgical Management of Carcinoid Valve Disease-Mechanical versus Tissue Valves
Introduction: The prosthetic valve of choice in patients with carcinoid valve disease (CVD) remains controversial due to the limited life expectancy of patients with advanced-stage neuroendocrine tumors (NETs) on one hand, and concerns regarding structural valve deterioration (SVD) on the other.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: MD Simona Glasberg
Authors: Glasberg S, Atlan J, Korach A, Dabah A, ...
#951 SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)
Introduction: Somatostatin analogs can reduce incidence/severity of CS symptoms but their impact on pt satisfaction needs further investigation.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Professor Philippe Ruszniewski
Keywords: PRO
#1178 Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study
Introduction: CS associated with NETs can have a negative impact on patients’ QoL.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Philippe Ruszniewski
Keywords: quality of life